Adding Ibrutinib Improves the Efficacy of Liso-Cel in R/R CLLJanuary 28th 2022
Chimeric antigen receptor T-cell therapies have demonstrated potential in chronic lymphocytic leukemia. However, T-cell dysfunction that is inherent to the disease, including reduced proliferative and cytotoxic capacities, limits the efficacy of this approach, according to an expert.
Clinical Benefit of Enzalutamide Is Elucidated in Oligometastatic Hormone-Sensitive Prostate CancerJanuary 27th 2022
Current findings validate and support the clinical utility of enzalutamide regardless of metastatic burden or type of oligometastatic disease, according to the investigators.
Longer Follow-Up Shows Improved DFS With Nivolumab in MIUCJanuary 26th 2022
According to Matthew Galsky, MD, results from the CheckMate-274 clinical trial support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial cancer after radical resection.
Immunotherapy Sparks Excitement for New Cervical Cancer TreatmentsJanuary 25th 2022
Immunotherapy has especially demonstrated broad activity in cervical cancer, fueling development in this area and providing further signs of hope for new treatment options to come into the landscape with greater efficacy and manageable safety profiles.